Skip to navigation Skip to content

Clinical Trial: Ocrelizumab for Preventing MS in Individuals With Radiologically Isolated Disease

Share

Details
Type of MS: RRMS
Treatment mode of action: To delay progression to MS
Number of Subjects: 100
Medication: ocrelizumab vs. placebo
Location: California|Connecticut|District of Columbia|Massachusetts|Missouri|Nevada|New York|Ohio|Oklahoma|Pennsylvania|Utah|Wisconsin
Institutions:

Multicenter, US

Contact Information
Please see list of sites below.

Funding:

Grant from Genentech to Yale University

Description

“Radiologically isolated syndrome” (RIS) is diagnosed when it is discovered that someone has brain MRI abnormalities similar in appearance and location to abnormalities seen in people with MS. People with RIS are typically otherwise healthy and without any symptoms common for MS. However, up to 50% of people with RIS do go on to develop MS within 10 years. Some risk factors for developing MS, like age, spinal fluid abnormalities, and location of suspicious lesions, have been identified. However, right now, there is no treatment for RIS. Individuals with RIS typically follow up regularly with a neurologist who keeps a close eye on them, looking for signs of MS.
 
The CELLO study is testing whether giving a short course of immune suppressing medication to people with RIS might prevent MS symptoms from ever developing. To study this, we will give half of our study participants an immune suppressing medication called ocrelizumab, and the other half an inactive placebo. We will then compare their symptoms and their MRI scans over time. Participants will be followed in the CELLO study for about 4 years. There are usually 2-3 study visits required per year.
 
Participants in the CELLO study will contribute MRIs, blood, spinal fluid and oral swabs throughout the study. Examining these specimens will help generate important information about how the immune system behaves in RIS. 

Contact Information for Each Site

Cleveland Clinic Melen Center, Cleveland, OH
Principal Investigator: Dr Daniel Ontaneda
PI email: ontaned@ccf.org 
Contact for inquiries: Megan Elder elderm3@ccf.org 
Telephone: (216) 444-9730
Address:
Cleveland Clinic Melen Center
Mellen Center U10
9500 Euclid Ave.
Cleveland, OH 44195

Cleveland Clinic – Lou Ruvo Center for Brain Health (Las Vegas, NV)
Principal Investigator: Dr. Le Hua
PI email: hual@ccf.org
Contact for inquiries: Meagan Jensen healthybrains@ccf.org
Telephone: (702) 462-6804
Address: 
Cleveland Clinic – Lou Ruvo Center for Brain Health
888 West Bonneville Ave, 
Las Vegas, NV 89106

The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley MA
Principal Investigator: Dr. Joshua Katz
PI email: joshuakatz@elliotlewisms.org
Contact for inquiries: Elizabeth Douglas elizabethdouglas@elliotlewisms.org
Telephone: 781-591-8314
Address:
The Elliot Lewis Center for Multiple Sclerosis Care
110 Cedar Street, Suite 110, 
Wellesley MA 02481

Georgetown University, Washington, D.C.
Principal Investigator: Dr. Ben Osborne
PI email: bjo102@gunet.georgetown.edu
Contact for inquiries: Zsofia Parragh zp53@georgetown.edu 
Telephone: 202-702-9120
Address:
Pasquerilla Healthcare Center 
7th Floor, 3800 Reservoir Rd., NW, 
Washington, D.C. 20007

Oklahoma Medical Research Foundation, Oklahoma City, OK
Principal Investigator: Dr. Gabriel Pardo
PI email: Gabriel-pardo@omrf.org
Contact for inquiries: Micki Drake micki-drake@omrf.org or Kellie Kraus kellie-kraus@omrf.org
Telephone: (405) 271-6241
Address: 
Oklahoma Medical Research Foundation
825 NE 13th Street, 
Oklahoma City, OK 73104

University of Utah, Salt Lake City, UT
Principal Investigator: Dr. M. Mateo Paz Soldan
PI email: mateo.pazsoldan@hsc.utah.edu 
Contact for inquiries: Trieste Francis Trieste.francis@hsc.utah.edu 
Telephone: 801-587-3864
Address: 
University of Utah
729 Arapeen Dr.,
Salt Lake City, UT 84108

Washington University- St. Louis
Principal Investigator: Robert Naismith
PI email: naismithr@neuro.wustl.edu
Contact for inquiries: Susan Sommer foxs@wustl.edu
Telephone: 314-362-2017
Address:
Washington University School of Medicine
Department of Neurology
John L. Trotter MS Center
660 South Euclid Avenue, CB 8111
St. Louis, MO 63110

Northwell, New York NY
Principal Investigator: Asaff Harel, MD
PI email: aharel@northwell.edu
Contact for inquiries: Olivia Colón ocolon2@northwell.edu
Telephone: 516-405-5193
Address: 130 E 77th St, 8 Black Hall, New York NY 10075

UPENN, Philadelphia, PA
Principal Investigator: Rachel Brandstadter
PI email: Rachel.Brandstadter@Pennmedicine.upenn.edu
Contact for inquiries: Margaux Giardino, Carly Cherwony  MSresearch@pennmedicine.upenn.edu
Telephone: 215-662-2820
Address: 
Perelman Center for Advanced Medicine
3400 Civic Center Blvd, Philadelphia, PA 19104

Massachusetts General Hospital, Boston, MA
Principal Investigator: Farrah Mateen MD, PhD
PI email: fmateen@mgh.harvard.edu
Contact for inquiries: Meredith Hasoenhrl
Telephone: 617-726-4540
Address: Neurological Clinical Research Institute
165 Cambridge Street
Boston, MA 2114

Medical College of Wisconsin, Milwaukee, WI
Principal Investigator: Ahmed Obeidat
PI email: aobeidat@mcw.edu
Contact for inquiries: Pam Dailey pdailey@mcw.edu
Telephone: 262-689-1846
Address: Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226

Mount Sinai
Principal Investigator: Erin Beck
PI email: erin.beck@mssm.edu> 
Contact for inquiries: Faye Bourie faye.bourie@mssm.edu
Telephone: 212-241-9002
Address: Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
Box 1138
New York, NY 10029

USC, Los Angeles, CA.
Principal Investigator: Lilyana Amezcua
PI email: lamezcua@usc.edu 
Contact for inquiries: Sylvia William sylviawi@usc.edu
Telephone: 323.442.6833
Address: Keck School of Medicine of USC
1520 San Pablo St. Suite 3000
Los Angeles, CA. 90033

Yale University, New Haven, CT
Principal Investigator: Dr. Erin Longbrake
PI email: erin.longbrake@yale.edu
Contact for inquiries: MSresearch@yale.edu
Telephone: (203) 287-6100
Address: 
Yale University
6 Devine Street, Suite 2B
North Haven, CT 06473
 

Share


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.